Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low - Time to Sell?

Sana Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Sana Biotechnology shares hit a new 52-week low of $1.82, below their prior close of $1.85.
  • Analyst views are mixed, but the consensus remains Moderate Buy, with a $9.83 average price target; recent targets include $11 from Citi and $6 from Bank of America.
  • The company reported a quarterly loss of $0.14 per share, beating analyst expectations of a $0.15 loss. Institutional investors own 88.23% of its shares.
  • Five stocks to consider instead of Sana Biotechnology.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday. The stock traded as low as $1.82 and last traded at $1.8150, with a volume of 185,345 shares. The stock had previously closed at $1.85.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Citigroup lowered their target price on Sana Biotechnology to $11.00 and set a "buy" rating for the company in a report on Monday. Wall Street Zen upgraded shares of Sana Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Bank of America reduced their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Weiss Ratings cut shares of Sana Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, November 11th. Finally, TD Cowen raised shares of Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.83.

Get Our Latest Report on Sana Biotechnology

Sana Biotechnology Stock Performance

The company has a 50 day moving average of $2.62 and a 200 day moving average of $3.24. The stock has a market capitalization of $537.84 million, a price-to-earnings ratio of -3.37 and a beta of 2.30.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. As a group, research analysts expect that Sana Biotechnology, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Large investors have recently made changes to their positions in the company. Allworth Financial LP raised its holdings in Sana Biotechnology by 880.8% in the third quarter. Allworth Financial LP now owns 13,123 shares of the company's stock valued at $38,000 after acquiring an additional 11,785 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in Sana Biotechnology in the third quarter worth approximately $548,000. Goldman Sachs Group Inc. grew its holdings in Sana Biotechnology by 13.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,680,550 shares of the company's stock worth $7,814,000 after acquiring an additional 312,615 shares in the last quarter. Toronto Dominion Bank grew its holdings in Sana Biotechnology by 0.3% during the 3rd quarter. Toronto Dominion Bank now owns 1,978,964 shares of the company's stock worth $5,769,000 after acquiring an additional 6,583 shares in the last quarter. Finally, Palumbo Wealth Management LLC increased its position in shares of Sana Biotechnology by 39.6% in the 3rd quarter. Palumbo Wealth Management LLC now owns 83,462 shares of the company's stock valued at $243,000 after purchasing an additional 23,689 shares during the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company's research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sana Biotechnology Right Now?

Before you consider Sana Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.

While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines